Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BDTX-4933 |
| Synonyms | |
| Therapy Description |
BDTX-4933 inhibits BRAF mutations, including class 1, 2 and 3 mutations, and active RAF dimers, which potentially decreases tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 3415). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BDTX-4933 | BDTX4933|BDTX 4933 | BRAF Inhibitor 26 | BDTX-4933 inhibits BRAF mutations, including class 1, 2 and 3 mutations, and active RAF dimers, which potentially decreases tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 3415). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF class 2 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 2 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... |
| BRAF class 3 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 3 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... |
| BRAF class 1 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 1 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05786924 | Phase Ib/II | BDTX-4933 + Fluorouracil + Irinotecan + Leucovorin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Irinotecan + Leucovorin BDTX-4933 BDTX-4933 + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin BDTX-4933 + Gemcitabine + Nab-paclitaxel | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Recruiting | USA | 0 |